A Colorado-based online organic CBD retailer has carried on with moving its fulfilment centre to Texas, despite the ongoing COVID-19 pandemic.
CBD 100% Relief has moved the centre from Denver to Dallas, despite market conditions being, according to company CEO Daniel Sandoval, “challenging”.
He said: “The recent viral outbreak is not helping either, but we cannot cease operations. We have to take additional precautionary measures at our FDA-registered facility to ensure that our products remain sterile, and unfortunately limit direct contact with people.”
GW suggests another possible use for Epidyolex
The company behind the CBD-based medicine which has been approved in the US and EU for treating rare forms of childhood epilepsy has put forward a proposal to use it to treat a rare genetic condition.
GW Pharma has applied to the European Medicines Agency (EMA) for a Type II Variation for Epidyolex (known in the US as Epidiolex) to be used to treat tuberous sclerosis complex (TSC), a genetic condition which can cause epilepsy. It is not known how long it will take for the EMA to consider the application.
GW’s chief operating officer, Chris Tovey, said: “We look forward to working with the EMA to demonstrate GW’s cannabidiol oral solution’s potential in this new indication and hope to make this rigorously tested cannabis-based medicine available to a new group of patients through a potential approval in due course.”
Lawsuit alleges hemp plants were contaminated with pesticide
A CBD company is taking a grower to court, claiming it lied about the plants it sold being free from pesticides.
Papers filed at the US District Court of Vermont by Milton-based Newton Hill Labs state that it lost nearly $1m worth of sales after 5000 lbs of hemp sold to it by Salisbury, Maryland’s Bay Water Greens and Baywater farms contained high levels of azoxystrobin and propiconazole.
The lawsuit is also targeting Seattle-based Kush Tourism, which is said to have brokered the initial deal for $132,000 worth of hemp plants.
Elixinol rebrands to move away from medicinal image
The head of a company has said it decided to rebrand from medical cannabis to CBD because of the way in which the brand was perceived.
Leif Harrison, CEO Americas of Australian company Elixinol, said a change of approach was needed because it was seen as “masculine and medicinal”.
Earlier this year, Elixinol announced it would be selling its Hemp Foods Australia business to a subsidiary of Chinese company Shanghai Shunho New Materials and announced it would sell off land and other assets owned by its Nunyara business.
Kentucky hemp business goes bust
One of the first businesses in Kentucky’s hemp industry has filed for bankruptcy.
Atalo Holdings, from Winchester, filed for Chapter 7 bankruptcy protection in the Eastern District of Kentucky, citing a combination of contradictory regulatory advice, market pressures and a “failed capital commitment, which left the company unable to pay its creditors”.
The company, which was founded in 2014, had assets of between $10m and $50m and liabilities of $1m to $10m.
– CBD-Intel staff
Photo: Robert Hensley
CBD-Intel does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of CBD-Intel, does not accept any liability or responsibility for information or views published.